ARCA biopharma reports FY2021 net loss $19.3M, cash $53.4M; rNAPc2 data due late March 2022

Oruka Therapeutics, Inc.

Net loss $19.3M ($1.39/share) vs $9.7M ($2.07/share) in FY2020; total operating expenses $19.3M.
Cash and equivalents $53.4M at Dec 31, 2021, up from $49.1M; runway through mid-2023.
R&D expenses $13.8M (up from $5.0M) driven by rNAPc2 trial; FY2022 R&D expected similar.
Topline data from Phase 2b ASPEN-COVID-19 trial for rNAPc2 anticipated last week of March 2022.
Gencaro paper published in Heart Rhythm O2; company evaluating PRECISION-AF trial feasibility.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.